Key statistics
On Friday, Microbot Medical Inc (MBOT:NAQ) closed at 2.17, 73.60% above the 52 week low of 1.25 set on Mar 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.11 |
|---|---|
| High | 2.37 |
| Low | 2.06 |
| Bid | 2.19 |
| Offer | 2.21 |
| Previous close | 2.09 |
| Average volume | 3.86m |
|---|---|
| Shares outstanding | 67.16m |
| Free float | 67.16m |
| P/E (TTM) | -- |
| Market cap | 145.73m USD |
| EPS (TTM) | -0.4513 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
- Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption
- Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
- Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
- Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
- Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
- Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
- Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
- Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
- Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
More ▼
